GPP & Mortality Risk: New Study Findings
- Peopel suffering from generalized pustular psoriasis (GPP) face a significantly higher risk of death compared to the general population, according to a recent U.S. study.
- GPP, a rare autoinflammatory disease, is characterized by skin and systemic symptoms, including fever and fatigue.
- Researchers analyzed data from 2,630 GPP patients, 127,540 plaque psoriasis patients, and over 19.6 million individuals from the general population.
Generalized Pustular Psoriasis Linked to Increased Mortality Risk
Updated June 03, 2025
Peopel suffering from generalized pustular psoriasis (GPP) face a significantly higher risk of death compared to the general population, according to a recent U.S. study. The research,published in the Journal of Psoriasis and Psoriatic Arthritis,found that GPP patients have nearly five times the risk of all-cause mortality within one year and four times the risk over a longer period.
GPP, a rare autoinflammatory disease, is characterized by skin and systemic symptoms, including fever and fatigue. Unlike the more common plaque psoriasis, GPP involves unpredictable flares that severely impact a patient’s quality of life. The study leveraged US claims data from 2016 to 2019, comparing mortality rates among GPP patients, plaque psoriasis patients, and the general population.
Researchers analyzed data from 2,630 GPP patients, 127,540 plaque psoriasis patients, and over 19.6 million individuals from the general population. The one-year mortality rate for GPP-only patients was 1.0%, increasing to 5.7% over the maximum follow-up period.
The study revealed that the all-GPP cohort had a 4.93 times greater mortality risk at one year and a 3.98 times greater risk at maximum follow-up, compared to the general population. When compared to those with only plaque psoriasis, the all-GPP cohort still showed a significantly elevated mortality risk at maximum follow-up.
The researchers acknowledged limitations, including a lack of specific cause-of-death data and potential misclassification of diagnoses based on administrative claims. The absence of detailed clinical data, such as flare severity and treatment regimens, also posed a challenge.
Despite these limitations, the study underscores the critical need for improved clinical recognition, targeted therapies, and long-term management strategies for individuals with generalized pustular psoriasis.
“These findings fill a notable gap in the existing literature and highlight both the need for increased awareness of the mortality burden in GPP and the need for continuous treatment options for patients with GPP both during and after flares,” wrote the researchers.
What’s next
Further research is needed to explore specific causes of death in GPP patients and to develop more effective treatment approaches to reduce mortality risk and improve patient outcomes.